↓ Skip to main content

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

Overview of attention for article published in Targeted Oncology, February 2019
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter
2 X users
patent
3 patents

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
37 Mendeley
Title
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
Published in
Targeted Oncology, February 2019
DOI 10.1007/s11523-019-00620-0
Pubmed ID
Authors

Toshihiko Doi, James Chih-Hsin Yang, Kohei Shitara, Yoichi Naito, Ann-Lii Cheng, Akiko Sarashina, Linda C. Pronk, Yoshito Takeuchi, Chia-Chi Lin

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 37 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 16%
Researcher 5 14%
Student > Master 4 11%
Student > Ph. D. Student 3 8%
Student > Doctoral Student 2 5%
Other 5 14%
Unknown 12 32%
Readers by discipline Count As %
Medicine and Dentistry 9 24%
Biochemistry, Genetics and Molecular Biology 5 14%
Agricultural and Biological Sciences 3 8%
Nursing and Health Professions 2 5%
Chemistry 2 5%
Other 4 11%
Unknown 12 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2024.
All research outputs
#4,791,077
of 25,263,619 outputs
Outputs from Targeted Oncology
#62
of 610 outputs
Outputs of similar age
#101,624
of 450,013 outputs
Outputs of similar age from Targeted Oncology
#3
of 16 outputs
Altmetric has tracked 25,263,619 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 610 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,013 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.